全文获取类型
收费全文 | 414篇 |
免费 | 18篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 10篇 |
妇产科学 | 12篇 |
基础医学 | 40篇 |
口腔科学 | 9篇 |
临床医学 | 39篇 |
内科学 | 128篇 |
皮肤病学 | 1篇 |
神经病学 | 22篇 |
特种医学 | 15篇 |
外科学 | 90篇 |
预防医学 | 30篇 |
眼科学 | 4篇 |
药学 | 9篇 |
肿瘤学 | 22篇 |
出版年
2023年 | 3篇 |
2022年 | 6篇 |
2021年 | 21篇 |
2020年 | 8篇 |
2019年 | 12篇 |
2018年 | 11篇 |
2017年 | 13篇 |
2016年 | 7篇 |
2015年 | 6篇 |
2014年 | 11篇 |
2013年 | 22篇 |
2012年 | 32篇 |
2011年 | 17篇 |
2010年 | 10篇 |
2009年 | 8篇 |
2008年 | 12篇 |
2007年 | 24篇 |
2006年 | 19篇 |
2005年 | 19篇 |
2004年 | 18篇 |
2003年 | 16篇 |
2002年 | 16篇 |
2001年 | 10篇 |
2000年 | 11篇 |
1999年 | 14篇 |
1998年 | 1篇 |
1997年 | 2篇 |
1996年 | 1篇 |
1994年 | 5篇 |
1992年 | 3篇 |
1991年 | 12篇 |
1990年 | 17篇 |
1989年 | 8篇 |
1988年 | 8篇 |
1987年 | 10篇 |
1986年 | 3篇 |
1985年 | 3篇 |
1984年 | 1篇 |
1979年 | 2篇 |
1973年 | 5篇 |
1970年 | 1篇 |
1968年 | 3篇 |
1967年 | 2篇 |
1966年 | 2篇 |
1965年 | 1篇 |
排序方式: 共有436条查询结果,搜索用时 15 毫秒
11.
12.
Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy 总被引:1,自引:0,他引:1
Offidani M Corvatta L Marconi M Malerba L Mele A Olivieri A Brunori M Catarini M Candela M Capelli D Montanari M Rupoli S Leoni P 《European journal of haematology》2004,72(6):403-409
OBJECTIVES: Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities. We have investigated the common and rare side-effects, especially analysing peripheral neuropathy, in order to optimise the thalidomide dose for minimizing this harmful side-effect. METHODS: Fifty-nine patients were treated with thalidomide alone or combined with oral melphalan. The median age was 69 yr. The initial dose of thalidomide was 100 mg/day increasing weekly by 100 mg increments until a maximum dose of 400 mg was attained. Melphalan was administered at a dose of 0.20 mg/kg/d for 4 d every 28 d. RESULTS AND CONCLUSIONS: Nearly one-fourth of patients discontinued thalidomide because of toxicity. Constipation (71%), somnolence (36%) and fatigue (20%) were the most common side-effects and they were not dose dependent. Peripheral neuropathy occurred in 39% of patients and a thalidomide median daily dose of more than 150 mg was significantly associated with higher frequency and actuarial risk of peripheral neuropathy without improving the response rate. Deep venous thrombosis was observed in 7% of patients and other side-effects were rare. In patients with advanced multiple myeloma we found that a thalidomide daily dose of 150 mg minimizes peripheral neuropathy without jeopardizing response and survival. 相似文献
13.
Candela F Serrano P Arriero JM Teruel A Reyes D Calpena R 《Diseases of the colon and rectum》1999,42(1):110-112
PURPOSE: A case of anal tuberculosis in an otherwise asymptomatic patient with bleeding anal ulcers is presented. The clinical features of this entity and the problems in differential diagnosis between anal infectious vs. inflammatory diseases are discussed. METHODS: The management and outcome of the case of an adult patient who presented with perianal ulcers is described. RESULTS: On a three-drug antituberculous regimen, symptoms abated, radiographic infiltrates improved, and perianal ulcers healed. CONCLUSION: Anal tuberculosis is an extremely rare disease. A tuberculous origin must be considered when the cause of perianal ulcers is unclear to avoid undesirable delays in the diagnosis and treatment of this disease. 相似文献
14.
J Báguena Candela 《The American journal of cardiology》1987,59(16):48H-52H
An 8-center European clinical trial has established that pirmenol in dosages up to 400 mg daily is effective and safe for treating stable, high frequency, ventricular ectopy. At dosages of 300 mg and 400 mg of pirmenol a day, the average frequency of ectopy/hour decreased markedly compared with baseline values. The percentage of responders (premature ventricular contraction suppression of 70% compared with baseline) among the patients receiving 300 mg or 400 mg of pirmenol/day was significantly higher than in the placebo group. Observation of the frequency of reported adverse experiences, clinical laboratory tests and electrocardiographic tracings shows that dosages of pirmenol up to 400 mg daily were well tolerated. 相似文献
15.
D J Kereiakes E J Topol B S George C W Abbottsmith R S Stack R J Candela W W O'Neill L C Anderson R M Califf 《American heart journal》1989,118(2):199-207
Coronary bypass surgery was performed before hospital discharge on 82 (21%) of 386 consecutive patients enrolled in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) multicenter trial of intravenous tissue plasminogen activator and coronary angioplasty for acute myocardial infarction. Time from infarct symptom onset to coronary bypass surgery was 7.3 +/- 1.9 hours for 24 patients operated upon on an emergency basis and 9.3 +/- 5.2 days for 58 patients having late in-hospital surgery. There were no operative deaths and five in-hospital deaths in the surgical group, all of which occurred in patients with preoperative cardiogenic shock. Although patients in the surgical group were older (59.7 +/- 10.4 years versus 54.9 +/- 10.2 years; p = 0.03), had more extensive coronary artery disease (42% three-vessel disease versus 11%; p = 0.001), and had a higher incidence of anterior wall myocardial infarction (48% versus 39%; p = 0.02), in-hospital mortality for the surgical group (6%) was similar to that in 301 patients not undergoing surgery (7%) in this trial. For patients discharged from the hospital, mortality at 1 year was 2.5% in the surgical group and 1.8% in patients not having coronary bypass surgery before hospital discharge. At a 1 year follow-up, there were no significant differences in the frequency of cardiac or noncardiac-related hospitalizations or in event-free survival between surgical and nonsurgical groups. The majority of patients in both groups considered themselves to be in excellent or good condition. Coronary bypass surgery can be performed with low morbidity and mortality rates in close temporal association to acute myocardial infarction.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
16.
17.
Evaluation of refrigerated platelet concentrates supplemented with low doses of second messenger effectors 总被引:3,自引:0,他引:3
Pérez-Ceballos E Rivera J Lozano ML Candela MJ Corral J Guerrero JA Vicente V 《Clinical and laboratory haematology》2004,26(4):275-286
With the goal of producing haemostatically effective platelet concentrates (PCs) with a longer shelf-life, we aimed to identify a simple combination of platelet inhibitors, with a low pharmacological load, which could avoid the unacceptable loss of platelets stored under refrigerated conditions. PCs stored with different combinations of second messenger effectors were analysed at days 5, 10 and 15 of storage and compared with those supplemented with ThromboSol--a combination of six platelet inhibitors that protects cells from cold damage. The following parameters were analysed: platelet counts, biochemical parameters (glucose, pH, bicarbonate, lactate), cell lysis (lactic dehydrogenase, LDH), membrane glycoproteins (GPs), platelet aggregation, fibrinogen binding and hypotonic shock response. We characterized the combination of amiloride and sodium nitroprusside (at 1/2 the dose included in ThromboSol). This was found to be similar to ThromboSol and superior to nontreated units in the prevention of cold-induced platelet aggregation at day 15 of storage (maintenance of 78% and 80% of initial platelet counts, respectively), preservation of GPIbalpha (11% and 12% better maintenance of mean fluorescence intensity compared with control units, respectively), and reduced cell lysis (13% and 11% decrease in supernatant LDH, respectively). The reduced pharmacological load with the identified solution compared with ThromboSol is an argument in favour of the potential use of these agents when designing strategies to improve PC storage. 相似文献
18.
Irigoyen MB Felippo ME Primiani L Candela M Bianco RP De Bracco MM Galassi N 《Haemophilia》2012,18(3):437-443
The development of inhibitors is a complication of replacement treatment in Haemophilia. Loss of factor VIII-specific memory B cells in the spleen is associated with down regulation of antibodies in mice treated with high doses of FVIII, but changes in B cell memory have not been described in haemophilic patients. The aim of this study was to evaluate the phenotype of circulating lymphocytes in severe haemophilia A. Twenty patients with inhibitors (PI), 22 without inhibitors (P), nine patients during immune tolerance induction (ITI) treatment and 20 healthy donors (HD) were included. Peripheral blood lymphocytes were examined using flow cytometry. Anti-FVIII antibodies were measured using Bethesda and flow cytometry. Percentages of T subsets and B lymphocytes were similar in all groups. In contrast, memory B cells (CD27+) were decreased in PI and P compared with HD, but the level of significance was higher in PI (P = 0.001) than P (P = 0.01). PI with high level of anti-FVIII antibodies presented the lowest B memory values. CD70 expression was also lowest in PI. Non-switched CD27+ subpopulation (IgD+) was prevalent in PI, but did not show statistical significance. When ITI failed, the percentages of CD27+ B cells after 12 months of ITI were lowest. In a longitudinal study performed in four patients, an increased percentage of CD27+ and CD70+ B cells during ITI was found. This work suggests that different peripheral lymphocyte markers, such as CD27 and CD70 on B cells, may be helpful to evaluate anti-FVIII response and to monitor the success of ITI. 相似文献
19.
Raynaud C Meibom KL Lety MA Dubail I Candela T Frapy E Charbit A 《Infection and immunity》2007,75(1):536-541
Francisella tularensis is a highly infectious bacterial pathogen, responsible for the zoonotic disease tularemia. We screened a bank of transposon insertion mutants of F. tularensis subsp. holarctica LVS for colony morphology alterations and selected a mutant with a transposon insertion in wbtA, the first gene of the predicted lipopolysaccharide O-antigen gene cluster. Inactivation of wbtA led to the complete loss of O antigen, conferred serum sensitivity, impaired intracellular replication, and severely attenuated virulence in the mouse model. Notably, this mutant afforded protection against a challenge against virulent LVS. 相似文献
20.
Monti G Pioltelli P Saccardo F Campanini M Candela M Cavallero G De Vita S Ferri C Mazzaro C Migliaresi S Ossi E Pietrogrande M Gabrielli A Galli M Invernizzi F 《Archives of internal medicine》2005,165(1):101-105
BACKGROUND: Some patients with cryoglobulinemic syndrome (CS) develop frank non-Hodgkin lymphoma (NHL), but the incidence and timing of this event are still poorly defined. METHODS: A retrospective multicenter study was performed of hepatitis C virus-positive patients with CS observed in 11 Italian centers belonging to the Italian Group for the Study of Cryoglobulinemia. RESULTS: The inclusion criteria were satisfied by 1,255 patients. During a cumulative follow-up of 8,928 patient-years, 59 cases of NHL were diagnosed, for an estimated rate of 660.8 new cases per 100,000 patient-years with 224.1 new cases of aggressive NHL subtypes per 100,000 patient-years. More than 90% of the patients developing NHLs had type II cryoglobulins. The NHLs were classified as nonaggressive in 31 cases (53%), aggressive in 20 (34%), and mucosa-associated lymphoid tissue lymphomas in 6 (10%); 2 cases were unclassifiable. The median time from the diagnosis of CS to the clinical onset of NHL was 6.26 years (range, 0.81-24 years). The clinical course and response to chemotherapy in the patients with CS who had NHL were similar to those usually described in patients with NHL without CS; the course of the CS only marginally benefited from chemotherapy. CONCLUSIONS: The overall risk of NHL in patients with CS is about 35 times higher than in the general population (12 times higher if nonaggressive lymphomas are excluded). The presence of CS did not significantly affect the treatment of newly diagnosed lymphomas. 相似文献